The US FDA's carryover user fee funds have continued to dwindle, but the agency nevertheless had an active week of product decisions. Here's your news in brief:
FDA granted at least three approvals during the week, most notably to Samsung Bioepis Co. Ltd.'s Herceptin (trastuzumab) biosimilar Ontruzant (trastuzumab-dttb). The nod to Ontruzant marks the agency's third...